Eli Lilly may face FDA warning letter after recent inspection at COVID-19 antibody plant found more issues: report

Eli Lilly's chances at an emergency use authorization for a COVID-19 antibody took a big hit after a major trial was stopped for safety concerns and the FDA flagged problems at a manufacturing site producing the therapy. Now, the FDA is back for more, and it could spell even bigger problems.